Over a month ago |
Recommendations
|
Argus raised the… Argus raised the firm's price target on Stryker to $285 from $270 and keeps a Buy rating on the shares. The analyst cites the company's Q4 earnings beat while noting that Stryker enters 2023 with a robust new order book in its MedSurg segment and higher procedural volume in its Orthopedics & Spine segment. The stock's valuation of 23-times expected forward earnings is above the average multiple of 21-times in the firm's coverage universe of medical device stocks, but Stryker's growth opportunities and success in integrating acquisitions support this premium valuation, the firm tells investors in a research note. ShowHide Related Items >><< - 02/17/23
- Stryker's Q Guidance System for cranial applications receives FDA clearance
- 02/13/23
- Stryker exec Menon sells 2,161 common shares
- 02/06/23
- Stryker CFO Boehnlein sells $6.8M in common stock
- 12/07/22
- Stryker raises quarterly dividend 7.9% to 7.5c per share
- 02/02/23 Barclays
- Stryker price target raised to $283 from $265 at Barclays
- 02/01/23 Loop Capital
- Stryker price target raised to $290 from $245 at Loop Capital
- 02/01/23 BTIG
- Stryker price target raised to $281 from $268 at BTIG
- 02/01/23 Canaccord
- Stryker price target raised to $250 from $220 at Canaccord
- 01/31/23
- Stryker sees FY23 adjusted EPS $9.85-$10.15, consensus $9.86
- 01/31/23
- Stryker reports Q4 adjusted EPS $3.00, consensus $2.84
- 10/31/22
- Stryker reports Q3 adjusted EPS $2.12, consensus $2.23
- 10/31/22
- Notable companies reporting after market close
- 02/01/23
- Fly Intel: Pre-market Movers
- 01/31/23
- Fly Intel: After-Hours Movers
- 01/25/23
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 11/01/22
- What You Missed On Wall Street On Tuesday
- 02/01/23
- Early notable gainers among liquid option names on February 1st
- 01/31/23
- Stryker options imply 2.7% move in share price post-earnings
- 10/31/22
- Stryker options imply 3.8% move in share price post-earnings
|
Hot Stocks
|
Stryker announced that… Stryker announced that its Q Guidance System with Cranial Guidance Software received 510(k) clearance from the U.S. Food and Drug Administration. The Q Guidance System is an image-based planning and intraoperative guidance system designed to support cranial surgeries, the firm says. Recently launched in September 2022, the Q Guidance System for spinal applications is currently available on the market. "The FDA clearance of Stryker's Q Guidance System with Cranial Guidance Software is a key milestone, which will help lead the transformation of cranial navigation and surgery," said Robbie Robinson, president of Stryker's Spine division. "Our robust pipeline of iterative launches reinforces our commitment to making industry-leading investments focused on providing advanced navigation products and differentiated technologies that our surgeon customers have come to expect." ShowHide Related Items >><< - 02/13/23
- Stryker exec Menon sells 2,161 common shares
- 02/06/23
- Stryker CFO Boehnlein sells $6.8M in common stock
- 12/07/22
- Stryker raises quarterly dividend 7.9% to 7.5c per share
- 10/31/22
- Stryker expects adverse EPS, revenue impact from foreign exchange rates
- 02/02/23 Barclays
- Stryker price target raised to $283 from $265 at Barclays
- 02/01/23 Loop Capital
- Stryker price target raised to $290 from $245 at Loop Capital
- 02/01/23 BTIG
- Stryker price target raised to $281 from $268 at BTIG
- 02/01/23 Canaccord
- Stryker price target raised to $250 from $220 at Canaccord
- 01/31/23
- Stryker sees FY23 adjusted EPS $9.85-$10.15, consensus $9.86
- 01/31/23
- Stryker reports Q4 adjusted EPS $3.00, consensus $2.84
- 10/31/22
- Stryker reports Q3 adjusted EPS $2.12, consensus $2.23
- 10/31/22
- Notable companies reporting after market close
- 02/01/23
- Fly Intel: Pre-market Movers
- 01/31/23
- Fly Intel: After-Hours Movers
- 01/25/23
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 11/01/22
- What You Missed On Wall Street On Tuesday
- 02/01/23
- Early notable gainers among liquid option names on February 1st
- 01/31/23
- Stryker options imply 2.7% move in share price post-earnings
- 10/31/22
- Stryker options imply 3.8% move in share price post-earnings
|
Hot Stocks
|
In a regulatory filing,… In a regulatory filing, Stryker group president Viju Menon disclosed the sale of 2,161 common shares of the company on February 9 at a price of $264.3065 per share. ShowHide Related Items >><< - 02/06/23
- Stryker CFO Boehnlein sells $6.8M in common stock
- 12/07/22
- Stryker raises quarterly dividend 7.9% to 7.5c per share
- 10/31/22
- Stryker expects adverse EPS, revenue impact from foreign exchange rates
- 09/20/22
- Stryker receives FDA 510(k) clearance for OptaBlate bone tumor ablation system
- 02/02/23 Barclays
- Stryker price target raised to $283 from $265 at Barclays
- 02/01/23 Loop Capital
- Stryker price target raised to $290 from $245 at Loop Capital
- 02/01/23 BTIG
- Stryker price target raised to $281 from $268 at BTIG
- 02/01/23 Canaccord
- Stryker price target raised to $250 from $220 at Canaccord
- 01/31/23
- Stryker sees FY23 adjusted EPS $9.85-$10.15, consensus $9.86
- 01/31/23
- Stryker reports Q4 adjusted EPS $3.00, consensus $2.84
- 10/31/22
- Stryker reports Q3 adjusted EPS $2.12, consensus $2.23
- 10/31/22
- Notable companies reporting after market close
- 02/01/23
- Fly Intel: Pre-market Movers
- 01/31/23
- Fly Intel: After-Hours Movers
- 01/25/23
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 11/01/22
- What You Missed On Wall Street On Tuesday
- 02/01/23
- Early notable gainers among liquid option names on February 1st
- 01/31/23
- Stryker options imply 2.7% move in share price post-earnings
- 10/31/22
- Stryker options imply 3.8% move in share price post-earnings
|
Hot Stocks
|
In a regulatory filing,… In a regulatory filing, Stryker disclosed that its CFO Glenn Boehnlein had sold 24.4K shares of its common stock during February 2nd in a total transaction size of $6.8M. ShowHide Related Items >><< - $271.36 /
-11.71 (-4.14%) - 12/07/22
- Stryker raises quarterly dividend 7.9% to 7.5c per share
- 10/31/22
- Stryker expects adverse EPS, revenue impact from foreign exchange rates
- 09/20/22
- Stryker receives FDA 510(k) clearance for OptaBlate bone tumor ablation system
- $271.36 /
-11.71 (-4.14%) - 02/02/23 Barclays
- Stryker price target raised to $283 from $265 at Barclays
- 02/01/23 Loop Capital
- Stryker price target raised to $290 from $245 at Loop Capital
- 02/01/23 BTIG
- Stryker price target raised to $281 from $268 at BTIG
- 02/01/23 Canaccord
- Stryker price target raised to $250 from $220 at Canaccord
- $271.36 /
-11.71 (-4.14%) - 01/31/23
- Stryker sees FY23 adjusted EPS $9.85-$10.15, consensus $9.86
- 01/31/23
- Stryker reports Q4 adjusted EPS $3.00, consensus $2.84
- 10/31/22
- Stryker reports Q3 adjusted EPS $2.12, consensus $2.23
- 10/31/22
- Notable companies reporting after market close
- $271.36 /
-11.71 (-4.14%) - 02/01/23
- Fly Intel: Pre-market Movers
- 01/31/23
- Fly Intel: After-Hours Movers
- 01/25/23
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 11/01/22
- What You Missed On Wall Street On Tuesday
- $271.36 /
-11.71 (-4.14%) - 02/01/23
- Early notable gainers among liquid option names on February 1st
- 01/31/23
- Stryker options imply 2.7% move in share price post-earnings
- 10/31/22
- Stryker options imply 3.8% move in share price post-earnings
|
Recommendations
|
Barclays analyst Matt… Barclays analyst Matt Miksic raised the firm's price target on Stryker to $283 from $265 and keeps an Overweight rating on the shares. The company delivered "robust" Q4 organic growth, earnings guidance above estimates and tempered organic sales guidance, the analyst tells investors in a research note. The firm believes Stryker's "strong momentum" and new product launches in robotic surgery, ortho implants and capital equipment position the company for potential upward revisions throughout 2023. ShowHide Related Items >><< - $278.90 /
+24.97 (+9.83%) - 12/07/22
- Stryker raises quarterly dividend 7.9% to 7.5c per share
- 10/31/22
- Stryker expects adverse EPS, revenue impact from foreign exchange rates
- 09/20/22
- Stryker receives FDA 510(k) clearance for OptaBlate bone tumor ablation system
- $278.90 /
+24.97 (+9.83%) - 02/01/23 Loop Capital
- Stryker price target raised to $290 from $245 at Loop Capital
- 02/01/23 BTIG
- Stryker price target raised to $281 from $268 at BTIG
- 02/01/23 Canaccord
- Stryker price target raised to $250 from $220 at Canaccord
- 02/01/23 Truist
- Stryker price target raised to $275 from $257 at Truist
- $278.90 /
+24.97 (+9.83%) - 01/31/23
- Stryker sees FY23 adjusted EPS $9.85-$10.15, consensus $9.86
- 01/31/23
- Stryker reports Q4 adjusted EPS $3.00, consensus $2.84
- 10/31/22
- Stryker reports Q3 adjusted EPS $2.12, consensus $2.23
- 10/31/22
- Notable companies reporting after market close
- $278.90 /
+24.97 (+9.83%) - 02/01/23
- Fly Intel: Pre-market Movers
- 01/31/23
- Fly Intel: After-Hours Movers
- 01/25/23
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 11/01/22
- What You Missed On Wall Street On Tuesday
- $278.90 /
+24.97 (+9.83%) - 02/01/23
- Early notable gainers among liquid option names on February 1st
- 01/31/23
- Stryker options imply 2.7% move in share price post-earnings
- 10/31/22
- Stryker options imply 3.8% move in share price post-earnings
|
Options
|
Notable gainers among… Notable gainers among liquid option names this morning include Stryker (SYK) $274.57 +20.76, Advanced Micro (AMD) $79.61 +4.46, Old Dominion (ODFL) $352.23 +18.99, Thermo Fisher (TMO) $595.59 +25.26, and Edwards Lifesciences (EW) $80.09 +3.39. ShowHide Related Items >><< - $583.00 /
+12.86 (+2.26%) - 01/24/23
- Thermo Fisher, AstraZeneca team on CDx test for Tagrisso
- 01/12/23
- Thermo Fisher joins Momentum Labs as a founding sponsor of biotech hub
- 01/03/23
- Thermo Fisher completes acquisition of The Binding Site Group, sees accretion
- 01/03/23
- Aslan, Thermo Fisher announce partnership for manufacturing eblasakimab
- $273.00 /
+19.07 (+7.51%) - 12/07/22
- Stryker raises quarterly dividend 7.9% to 7.5c per share
- 10/31/22
- Stryker expects adverse EPS, revenue impact from foreign exchange rates
- 09/20/22
- Stryker receives FDA 510(k) clearance for OptaBlate bone tumor ablation system
- $356.00 /
+22.715 (+6.82%) - 02/01/23
- Old Dominion boosts dividend 33.3% to 40c
- 02/01/23
- Old Dominion:Q4 operating ratio up 240 basis points to 71.2% vs. last year
- 01/31/23
- Old Dominion names Kevin Freeman to succeed Greg Gantt as president, CEO
- 12/15/22
- Old Dominion announces 4.9% general rate increase
- 12/08/22
- Edwards Lifesciences CEO Michael Mussallem to retire, Bernard Zovighian succeeds
- 11/01/22
- Edwards Lifesciences authorizes $750M accelerated share repurchase
- 10/28/22
- Edwards Lifesciences falls -16.6%
- 10/28/22
- Edwards Lifesciences falls -14.3%
- 01/20/23
- AMD identified as respondent in ITC investigation of certain integrated circuits
- 01/19/23
- AMD adaptive computing tech enables DENSO LiDAR system
- 01/11/23
- AMD CFO Devinder Kumar to retire, Jean Hu appointed new CFO
- 12/20/22
- EU opens antitrust probe into Broadcom's proposed $61B VMware bid
- $273.00 /
+19.07 (+7.51%) - 02/01/23 Loop Capital
- Stryker price target raised to $290 from $245 at Loop Capital
- 02/01/23 BTIG
- Stryker price target raised to $281 from $268 at BTIG
- 02/01/23 Canaccord
- Stryker price target raised to $250 from $220 at Canaccord
- 02/01/23 Truist
- Stryker price target raised to $275 from $257 at Truist
- 02/01/23 Craig-Hallum
- Craig-Hallum downgrades AMD to Hold on slowing growth
- 02/01/23 Northland
- AMD guidance 'isn't great,' but 'not a disaster,' says Northland
- 02/01/23 Craig-Hallum
- AMD downgraded to Hold from Buy at Craig-Hallum
- 02/01/23 Morgan Stanley
- AMD's softer outlook 'still could be a relief' after Intel, says Morgan Stanley
- $356.00 /
+22.715 (+6.82%) - 01/30/23 Credit Suisse
- Old Dominion downgraded to Underperform from Neutral at Credit Suisse
- 01/20/23 Raymond James
- Old Dominion price target raised to $335 from $300 at Raymond James
- 01/17/23 BofA
- Schneider, Werner upgraded to Buy, XPO Logistics downgraded at BofA
- 01/17/23 BofA
- Old Dominion upgraded to Neutral from Underperform at BofA
- $583.00 /
+12.86 (+2.26%) - 01/24/23 Barclays
- Thermo Fisher price target raised to $630 from $570 at Barclays
- 01/03/23 Wells Fargo
- Thermo Fisher price target lowered to $505 from $525 at Wells Fargo
- 12/13/22 Deutsche Bank
- Thermo Fisher initiated with a Buy at Deutsche Bank
- 12/06/22 RBC Capital
- Thermo Fisher initiated with an Outperform at RBC Capital
- 02/01/23 Canaccord
- Edwards Lifesciences price target raised to $76 from $68 at Canaccord
- 01/31/23 Bernstein
- Edwards Lifesciences downgraded to Underperform from Outperform at Bernstein
- 01/30/23 Piper Sandler
- Edwards Lifesciences downgraded to Neutral from Overweight at Piper Sandler
- 12/12/22 Canaccord
- Edwards Lifesciences price target lowered to $73 from $78 at Canaccord
- $583.00 /
+12.86 (+2.26%) - 02/01/23
- Thermo Fisher sees Q1 EPS over 20% of full-year total, consensus $5.41
- 02/01/23
- Thermo Fisher sees FY23 adjusted EPS $23.70, consensus $23.21
- 02/01/23
- Thermo Fisher reports Q4 adjusted EPS $5.40, consensus $5.19
- 01/31/23
- Notable companies reporting before tomorrow's open
- $273.00 /
+19.07 (+7.51%) - 01/31/23
- Stryker sees FY23 adjusted EPS $9.85-$10.15, consensus $9.86
- 01/31/23
- Stryker reports Q4 adjusted EPS $3.00, consensus $2.84
- 10/31/22
- Stryker reports Q3 adjusted EPS $2.12, consensus $2.23
- 10/31/22
- Notable companies reporting after market close
- $356.00 /
+22.715 (+6.82%) - 02/01/23
- Old Dominion reports Q4 EPS $2.92, consensus $2.68
- 10/26/22
- Old Dominion reports Q3 EPS $3.36, consensus $3.07
- 01/31/23
- Edwards Lifesciences sees Q1 adjusted EPS 58c-64c, consensus 59c
- 01/31/23
- Edwards Lifesciences backs FY23 adjusted EPS $2.45-$2.60, consensus $2.50
- 01/31/23
- Edwards Lifesciences reports Q4 adjusted EPS 64c, consensus 61c
- 01/31/23
- AMD sees Q1 revenue $5.3B +/- $300M, consensus $5.48B
- 01/31/23
- AMD reports Q4 EPS 69c, consensus 67c
- 01/31/23
- Notable companies reporting after market close
- 11/01/22
- AMD cuts FY22 revenue view to $23.5B +/- $300M from $26.3B +/- $300M
- $583.00 /
+12.86 (+2.26%) - 10/30/22
- Thermo Fisher said to near $2.3B deal for Binding Site, Bloomberg reports
- $356.00 /
+22.715 (+6.82%) - 12/10/22
- Microsoft, Arista among stocks that can survive a triple whammy, Barron's says
- 01/30/23
- U.S. considers cutting off Huawei fully from U.S. suppliers, Bloomberg says
- 01/30/23
- U.S. considers cutting off Huawei fully from U.S. suppliers, Bloomberg says
- 01/11/23
- TSMC receives 3nm chip orders from Broadcom, DigiTimes reports
- 01/04/23
- China pauses chip industry investments as COVID resurges, Bloomberg reports
- $583.00 /
+12.86 (+2.26%) - 12/07/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 10/31/22
- What You Missed On Wall Street On Monday
- 10/31/22
- What You Missed On Wall Street This Morning
- $273.00 /
+19.07 (+7.51%) - 02/01/23
- Fly Intel: Pre-market Movers
- 01/31/23
- Fly Intel: After-Hours Movers
- 01/25/23
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 11/01/22
- What You Missed On Wall Street On Tuesday
- 01/31/23
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 12/08/22
- What You Missed On Wall Street On Thursday
- 12/08/22
- What You Missed On Wall Street This Morning
- 01/28/23
- Buy/Sell: Wall Street's top 10 stock calls this week
- 01/27/23
- Here's What You Missed in Crypto This Week
- $583.00 /
+12.86 (+2.26%) - 01/10/23
- Early notable gainers among liquid option names on January 10th
- $273.00 /
+19.07 (+7.51%) - 01/31/23
- Stryker options imply 2.7% move in share price post-earnings
- 10/31/22
- Stryker options imply 3.8% move in share price post-earnings
- $356.00 /
+22.715 (+6.82%) - 01/27/23
- Early notable gainers among liquid option names on January 27th
- 01/18/23
- Early notable gainers among liquid option names on January 18th
- 01/31/23
- Edwards Lifesciences options imply 5.3% move in share price post-earnings
- 12/05/22
- Edwards Lifesciences call volume above normal and directionally bullish
- 10/31/22
- Early notable gainers among liquid option names on October 31st
- 10/27/22
- Edwards Lifesciences options imply 4.1% move in share price post-earnings
- 02/01/23
- Notable open interest changes for February 1st
- 01/31/23
- Advanced Micro options imply 7.0% move in share price post-earnings
- 01/24/23
- Unusually active option classes on open January 24th
- 01/23/23
- Early notable gainers among liquid option names on January 23rd
|
On The Fly
|
Check out this morning's… ShowHide Related Items >><< - 02/01/23
- T-Mobile sees FY23 postpet net customer additions 5M-5.5M
- 01/19/23
- T-Mobile says it may incur 'significant expenses' over cyber incident
- 01/09/23
- Siyata Mobile to launch SD7 device across T-Mobile IoT data network
- 01/05/23
- Delta, T-Mobile to partner on free in-flight Wi-Fi for SkyMiles members
- $570.40 /
+6.335 (+1.12%) - 01/24/23
- Thermo Fisher, AstraZeneca team on CDx test for Tagrisso
- 01/12/23
- Thermo Fisher joins Momentum Labs as a founding sponsor of biotech hub
- 01/03/23
- Thermo Fisher completes acquisition of The Binding Site Group, sees accretion
- 01/03/23
- Aslan, Thermo Fisher announce partnership for manufacturing eblasakimab
- $253.76 /
+4.245 (+1.70%) - 12/07/22
- Stryker raises quarterly dividend 7.9% to 7.5c per share
- 10/31/22
- Stryker expects adverse EPS, revenue impact from foreign exchange rates
- 09/20/22
- Stryker receives FDA 510(k) clearance for OptaBlate bone tumor ablation system
- 01/31/23
- Snap expects to see full benefit of cost reductions in Q1
- 01/31/23
- Snap sees Q1 DAU 382M-384M, expects adjusted EBITDA breakeven in Q1
- 01/31/23
- Snap says the quarter 'materialized largely as expected'
- 01/31/23
- Snap says 'remains focused' on accelerating revenue growth.
- 02/01/23
- Peloton not forecasting spike in churn rate
- 02/01/23
- Peloton still sees revenue for the year to resemble seasonality of FY22
- 02/01/23
- Peloton: Precor meets significant need in commercial marketplace
- 02/01/23
- Peloton CEO says generated more revenue from subscriptions vs. hardware sales
- 01/24/23
- Altria Group trading resumes
- 01/24/23
- Altria Group trading halted, volatility trading pause
- 01/22/23
- Fly Intel: Top five weekend stock stories
- 12/19/22
- Cronos Group receives notice of relinquishment of warrant by Altria Group
- 11/02/22
- Brinker reports Q1 system-wide comparable restaurant sales growth 5.5%
- 10/25/22
- Brinker announces executive leadership changes
- 08/24/22
- Brinker: Q1 likely to be low point of operating results for FY23
- 08/24/22
- Brinker says 'mid-teens' restaurant margins achievable
- 01/31/23
- Chairman of Electronic Arts Wilson sells 5,000 shares of company stock
- 01/31/23
- Electronic Arts sees mid-single digit growth in net bookings in 2024
- 01/31/23
- Electronic Arts says taking more measured approach to Q4 game launches
- 01/31/23
- EA says 'FIFA Mobile' engagement up triple digits in Q3
- 11/02/22
- Dynatrace under pressure following Q2 beat, 2023 guidance cut
- 11/02/22
- Dynatrace names Jim Benson as CFO, succeeding Kevin Burns
- 10/27/22
- DXC Technology announces expanded partnership with Dynatrace
- 09/19/22
- Dynatrace to replace American Eagle in S&P 400 at open on 9/19
- 01/20/23
- AMD identified as respondent in ITC investigation of certain integrated circuits
- 01/19/23
- AMD adaptive computing tech enables DENSO LiDAR system
- 01/11/23
- AMD CFO Devinder Kumar to retire, Jean Hu appointed new CFO
- 12/20/22
- EU opens antitrust probe into Broadcom's proposed $61B VMware bid
- $570.40 /
+6.335 (+1.12%) - 01/24/23 Barclays
- Thermo Fisher price target raised to $630 from $570 at Barclays
- 01/03/23 Wells Fargo
- Thermo Fisher price target lowered to $505 from $525 at Wells Fargo
- 12/13/22 Deutsche Bank
- Thermo Fisher initiated with a Buy at Deutsche Bank
- 12/06/22 RBC Capital
- Thermo Fisher initiated with an Outperform at RBC Capital
- 11/10/22 UBS
- UBS downgrades Altria to Sell on consumer trade down risk
- 11/10/22 UBS
- Altria Group downgraded to Sell from Neutral at UBS
- 11/02/22 Morgan Stanley
- Philip Morris price target raised to $109 from $102 at Morgan Stanley
- 10/28/22 Stifel
- Altria JV news trumps 'rare' EPS miss, says Stifel
- 01/10/23 Barclays
- Dynatrace downgraded to Equal Weight from Overweight at Barclays
- 01/09/23 Truist
- Dynatrace price target lowered to $45 from $50 at Truist
- 01/03/23 Wells Fargo
- Dynatrace price target raised to $50 from $45 at Wells Fargo
- 12/15/22 Wedbush
- Wedbush initiates Dynatrace with a Neutral and $35 price target
- 01/30/23 Citi
- Peloton promotions drove improved traffic trends, says Citi
- 01/24/23 MKM Partners
- MKM Partners positive on Peloton heading into earnings
- 01/24/23 Baird
- Peloton downgraded to Neutral from Outperform at Baird
- 11/21/22 TD Cowen
- Peloton downgraded to Market Perform from Outperform at Cowen
- 01/24/23 Deutsche Bank
- Brinker price target raised to $38 from $34 at Deutsche Bank
- 01/05/23 Barclays
- Brinker price target lowered to $30 from $31 at Barclays
- 12/21/22 Jefferies
- Brinker downgraded to Hold from Buy at Jefferies
- 12/12/22 Goldman Sachs
- Brinker downgraded to Sell from Neutral at Goldman Sachs
- $253.76 /
+4.245 (+1.70%) - 02/01/23 Loop Capital
- Stryker price target raised to $290 from $245 at Loop Capital
- 02/01/23 BTIG
- Stryker price target raised to $281 from $268 at BTIG
- 02/01/23 Canaccord
- Stryker price target raised to $250 from $220 at Canaccord
- 02/01/23 Truist
- Stryker price target raised to $275 from $257 at Truist
- 02/01/23 Craig-Hallum
- Craig-Hallum downgrades AMD to Hold on slowing growth
- 02/01/23 Northland
- AMD guidance 'isn't great,' but 'not a disaster,' says Northland
- 02/01/23 Craig-Hallum
- AMD downgraded to Hold from Buy at Craig-Hallum
- 02/01/23 Morgan Stanley
- AMD's softer outlook 'still could be a relief' after Intel, says Morgan Stanley
- 01/17/23 KeyBanc
- Cogent price target raised to $71 from $64 at KeyBanc
- 01/13/23 Truist
- American Tower price target lowered to $275 from $325 at Truist
- 01/05/23 JPMorgan
- T-Mobile remains a top pick after preannouncement at JPMorgan
- 01/03/23 Wolfe Research
- T-Mobile downgraded to Peer Perform from Outperform at Wolfe Research
- 02/01/23 Rosenblatt
- Snap price target raised to $10 from $8 at Rosenblatt
- 02/01/23 Canaccord
- Snap price target lowered to $11 from $12 at Canaccord
- 02/01/23 Benchmark
- Benchmark downgrades 'too far behind' Snap to Hold after earnings
- 02/01/23 Susquehanna
- Snap price target raised to $10 from $8 at Susquehanna
- 02/01/23 Wells Fargo
- Electronic Arts price target lowered to $120 from $150 at Wells Fargo
- 02/01/23 Roth MKM
- Electronic Arts price target lowered to $112 from $131 at Roth Capital
- 02/01/23 Wedbush
- Electronic Arts price target lowered to $139 from $164 at Wedbush
- 02/01/23 TD Cowen
- Electronic Arts price target lowered to $136 from $158 at Cowen
- 02/01/23
- T-Mobile reports Q4 EPS $1.18, consensus $1.10
- 01/04/23
- T-Mobile sees FY22 postpaid net customer additions 6.4M
- $570.40 /
+6.335 (+1.12%) - 02/01/23
- Thermo Fisher sees FY23 adjusted EPS $23.70, consensus $23.21
- 02/01/23
- Thermo Fisher reports Q4 adjusted EPS $5.40, consensus $5.19
- 01/31/23
- Notable companies reporting before tomorrow's open
- $253.76 /
+4.245 (+1.70%) - 01/31/23
- Stryker sees FY23 adjusted EPS $9.85-$10.15, consensus $9.86
- 01/31/23
- Stryker reports Q4 adjusted EPS $3.00, consensus $2.84
- 10/31/22
- Stryker reports Q3 adjusted EPS $2.12, consensus $2.23
- 10/31/22
- Notable companies reporting after market close
- 01/31/23
- Snap sees Q1 revenue down 2%-10% y/y, consensus $1.08B
- 01/31/23
- Snap reports Q4 EPS 14c, consensus 11c
- 10/20/22
- Snap reports Q3 adjusted EPS 8c, consensus (1c)
- 02/01/23
- Peloton sees Q3 revenue $690M-$715M, consensus $692.14M
- 02/01/23
- Peloton reports Q2 EPS (98c), consensus (64c)
- 02/01/23
- Altria Group sees FY23 adjusted EPS $4.98-$5.13, consensus $5.05
- 02/01/23
- Altria Group reports Q4 adjusted EPS $1.18, consensus $1.17
- 02/01/23
- Brinker raises FY23 adjusted EPS $2.60-$2.90 from $2.45-$2.85, consensus $2.56
- 02/01/23
- Brinker reports Q2 EPS 76c, consensus 52c
- 01/31/23
- EA sees mid-single digit top and bottom line growth in FY24
- 01/31/23
- Electronic Arts cuts FY23 EPS view to $2.97-$3.11 from $3.11-$3.34
- 01/31/23
- Electronic Arts sees Q4 EPS 5c-20c, consensus $2.22
- 01/31/23
- Electronic Arts reports Q3 EPS 73, consensus $3.05
- 02/01/23
- Dynatrace raises FY23 adjusted EPS view to 87c-88c from 81c-83c
- 02/01/23
- Dynatrace sees Q4 adjusted EPS 22c-23c, consensus 21c
- 02/01/23
- Dynatrace reports Q3 adjusted EPS 25c, consensus 21c
- 01/31/23
- AMD sees Q1 revenue $5.3B +/- $300M, consensus $5.48B
- 01/31/23
- AMD reports Q4 EPS 69c, consensus 67c
- 01/31/23
- Notable companies reporting after market close
- 11/01/22
- AMD cuts FY22 revenue view to $23.5B +/- $300M from $26.3B +/- $300M
- 01/11/23
- T-Mobile considers acquisition of Ryan Reynolds' Mint Mobile, Bloomberg says
- 01/11/23
- T-Mobile considers acquisition of Ryan Reynolds' Mint Mobile, Bloomberg says
- 01/02/23
- Polish regulator accuses T-Mobile of misleading advertising, Reuters says
- 12/20/22
- FCC partisan deadlock shields wireless companies from $200M fine, WSJ reports
- $570.40 /
+6.335 (+1.12%) - 10/30/22
- Thermo Fisher said to near $2.3B deal for Binding Site, Bloomberg reports
- 01/25/23
- Feds to question Snapchat's role in fentanyl-laced pills sales, Bloomberg says
- 01/25/23
- Hawley to introduce bill to implement nationwide ban on TikTok, Fox reports
- 01/08/23
- Seattle public schools blame tech giants for social media harm, Reuters says
- 12/22/22
- TikTok parent ByteDance says staff improperly accessed user data, WSJ says
- 10/28/22
- Peloton co-founder doubled his pledge shares to cover margin calls, WSJ reports
- 10/27/22
- Peloton drops Kanye West music from platform, NY Post reports
- 10/11/22
- Peloton's Foley faced 'repeated' margin calls on money he borrowed, WSJ reports
- 10/06/22
- Peloton to cut 500 more jobs in turnaround effort, WSJ reports
- 01/25/23
- Juul in deal discussions with Philip Morris, Altria, Japan Tobacco, WSJ says
- 01/21/23
- Wells Fargo, Disney among stocks watched by value investors, Barron's says
- 01/07/23
- Philip Morris' stock about to get 'smoking hot,' Barron's says
- 12/12/22
- Supreme Court declines to halt California flavored tobacco ban, Bloomberg says
- 01/30/23
- EA's 'Dead Space' top-selling physical game in U.K., GI.biz says
- 01/23/23
- Nintendo's new 'Fire Emblem' top-selling physical game in U.K., GI.biz says
- 01/18/23
- Video game sales fell 13% y/y in Europe in December, GI.biz says
- 01/11/23
- Amazon Game Studios loses another key executive amid cutbacks, Bloomberg says
- 01/30/23
- U.S. considers cutting off Huawei fully from U.S. suppliers, Bloomberg says
- 01/30/23
- U.S. considers cutting off Huawei fully from U.S. suppliers, Bloomberg says
- 01/11/23
- TSMC receives 3nm chip orders from Broadcom, DigiTimes reports
- 01/04/23
- China pauses chip industry investments as COVID resurges, Bloomberg reports
- 01/20/23
- What You Missed On Wall Street On Friday
- 01/20/23
- What You Missed On Wall Street This Morning
- 01/19/23
- Fly Intel: After-Hours Movers
- 01/12/23
- What You Missed On Wall Street On Thursday
- $570.40 /
+6.335 (+1.12%) - 12/07/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 10/31/22
- What You Missed On Wall Street On Monday
- 10/31/22
- What You Missed On Wall Street This Morning
- 10/27/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- $253.76 /
+4.245 (+1.70%) - 01/31/23
- Fly Intel: After-Hours Movers
- 01/25/23
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 11/01/22
- What You Missed On Wall Street On Tuesday
- 11/01/22
- What You Missed On Wall Street This Morning
- 01/31/23
- Here's what Wall St. experts are saying about Snap ahead of earnings
- 01/25/23
- #SocialStocks: Musk refutes veracity of WSJ story that he seeks $3B in funding
- 01/18/23
- #SocialStocks: Meta fights scraping, Twitter interest payments coming due
- 01/24/23
- What You Missed On Wall Street On Tuesday
- 01/24/23
- What You Missed On Wall Street This Morning
- 01/24/23
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 12/27/22
- What You Missed On Wall Street On Tuesday
- 01/25/23
- What You Missed On Wall Street On Wednesday
- 11/10/22
- Fly Intel: Pre-market Movers
- 10/27/22
- What You Missed On Wall Street On Thursday
- 10/27/22
- What You Missed On Wall Street This Morning
- 12/21/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 08/24/22
- What You Missed On Wall Street On Wednesday
- 08/24/22
- What You Missed On Wall Street This Morning
- 08/24/22
- Fly Intel: Pre-market Movers
- 01/31/23
- What You Missed This Week in Video Games
- 01/24/23
- What You Missed This Week in Video Games
- 01/17/23
- What You Missed This Week in Video Games
- 01/10/23
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 11/02/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 11/02/22
- Fly Intel: Pre-market Movers
- 10/11/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 01/28/23
- Buy/Sell: Wall Street's top 10 stock calls this week
- 01/27/23
- Here's What You Missed in Crypto This Week
- 12/28/22
- T Mobile put volume heavy and directionally bearish
- 12/15/22
- T Mobile call volume above normal and directionally bullish
- 10/28/22
- Early notable gainers among liquid option names on October 28th
- 10/27/22
- T Mobile options imply 4.2% move in share price post-earnings
- $570.40 /
+6.335 (+1.12%) - 01/10/23
- Early notable gainers among liquid option names on January 10th
- $253.76 /
+4.245 (+1.70%) - 01/31/23
- Stryker options imply 2.7% move in share price post-earnings
- 10/31/22
- Stryker options imply 3.8% move in share price post-earnings
- 01/31/23
- Snap Inc. options imply 18.8% move in share price post-earnings
- 12/22/22
- Snap Inc. call volume above normal and directionally bullish
- 12/15/22
- Snap Inc. call volume above normal and directionally bullish
- 12/14/22
- Snap Inc. call volume above normal and directionally bullish
- 01/30/23
- Peloton Interactive call volume above normal and directionally bullish
- 01/24/23
- Peloton Interactive put volume heavy and directionally bearish
- 01/06/23
- Peloton Interactive call volume above normal and directionally bullish
- 12/15/22
- Largest borrow rate increases among liquid names
- 12/27/22
- Altria Group put volume heavy and directionally bearish
- 10/11/22
- Altria Group call volume above normal and directionally bullish
- 10/11/22
- Early notable gainers among liquid option names on October 11th
- 09/29/22
- Altria Group call volume above normal and directionally bullish
- 01/31/23
- Electronic Arts options imply 4.3% move in share price post-earnings
- 10/05/22
- Electronic Arts put volume heavy and directionally bearish
- 10/03/22
- Electronic Arts Inc. call volume above normal and directionally bullish
- 08/26/22
- Early notable gainers among liquid option names on August 26th
- 01/31/23
- Advanced Micro options imply 7.0% move in share price post-earnings
- 01/24/23
- Unusually active option classes on open January 24th
- 01/23/23
- Early notable gainers among liquid option names on January 23rd
- 01/09/23
- Early notable gainers among liquid option names on January 9th
|
Recommendations
|
Loop Capital analyst… Loop Capital analyst Jason Wittes raised the firm's price target on Stryker to $290 from $245 and keeps a Buy rating on the shares. The company's Q4 earnings and revenue topped expectations amid robust topline growth, though this was partially offset by negative currency headwinds and high inflationary pressure, the analyst tells investors in a research note. The firm "sees only upside" in the stock, though macro concerns do remain, Loop Capital added. ShowHide Related Items >><< - $253.76 /
+4.245 (+1.70%) - 12/07/22
- Stryker raises quarterly dividend 7.9% to 7.5c per share
- 10/31/22
- Stryker expects adverse EPS, revenue impact from foreign exchange rates
- 09/20/22
- Stryker receives FDA 510(k) clearance for OptaBlate bone tumor ablation system
- $253.76 /
+4.245 (+1.70%) - 02/01/23 BTIG
- Stryker price target raised to $281 from $268 at BTIG
- 02/01/23 Canaccord
- Stryker price target raised to $250 from $220 at Canaccord
- 02/01/23 Truist
- Stryker price target raised to $275 from $257 at Truist
- 02/01/23 RBC Capital
- Stryker price target raised to $288 from $284 at RBC Capital
- $253.76 /
+4.245 (+1.70%) - 01/31/23
- Stryker sees FY23 adjusted EPS $9.85-$10.15, consensus $9.86
- 01/31/23
- Stryker reports Q4 adjusted EPS $3.00, consensus $2.84
- 10/31/22
- Stryker reports Q3 adjusted EPS $2.12, consensus $2.23
- 10/31/22
- Notable companies reporting after market close
- $253.76 /
+4.245 (+1.70%) - 01/31/23
- Fly Intel: After-Hours Movers
- 01/25/23
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 11/01/22
- What You Missed On Wall Street On Tuesday
- 11/01/22
- What You Missed On Wall Street This Morning
- $253.76 /
+4.245 (+1.70%) - 01/31/23
- Stryker options imply 2.7% move in share price post-earnings
- 10/31/22
- Stryker options imply 3.8% move in share price post-earnings
|